BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37704352)

  • 21. MEK inhibitors in RASopathies.
    Bergqvist C; Wolkenstein P
    Curr Opin Oncol; 2021 Mar; 33(2):110-119. PubMed ID: 33395032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
    Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
    Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Anderson MK; Johnson M; Thornburg L; Halford Z
    Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.
    Waggoner DJ; Towbin J; Gottesman G; Gutmann DH
    Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
    Ma Y; Gross AM; Dombi E; Pemov A; Choi K; Chaney K; Rhodes SD; Angus SP; Sciaky N; Clapp DW; Ratner N; Widemann BC; Rios JJ; Elefteriou F
    Genet Med; 2020 Nov; 22(11):1786-1793. PubMed ID: 32601387
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Chaney KE; Perrino MR; Kershner LJ; Patel AV; Wu J; Choi K; Rizvi TA; Dombi E; Szabo S; Largaespada DA; Ratner N
    Cancer Res; 2020 Nov; 80(21):4720-4730. PubMed ID: 32816910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
    Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
    Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
    Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
    Kim A; Dombi E; Tepas K; Fox E; Martin S; Wolters P; Balis FM; Jayaprakash N; Turkbey B; Muradyan N; Choyke PL; Reddy A; Korf B; Widemann BC
    Pediatr Blood Cancer; 2013 Mar; 60(3):396-401. PubMed ID: 22961690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
    Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
    J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1.
    Mateos ME; López-Laso E; Vicente J; Ortega R; Vázquez F; Pérez-Navero JL
    Pediatr Int; 2020 Jul; 62(7):857-859. PubMed ID: 32027426
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
    Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
    Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas.
    Hua C; Zehou O; Ducassou S; Minard-Colin V; Hamel-Teillac D; Wolkenstein P; Valeyrie-Allanore L
    Pediatrics; 2014 Jun; 133(6):e1792-7. PubMed ID: 24864177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series.
    Coltin H; Perreault S; Larouche V; Black K; Wilson B; Vanan MI; Gupta AA; Morgenstern DA; Parkin PC; Bouffet E; Ramaswamy V
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29633. PubMed ID: 35289492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heightened CXCR4 and CXCL12 expression in NF1-associated neurofibromas.
    Karaosmanoglu B; Kocaefe ÇY; Söylemezoğlu F; Anlar B; Varan A; Vargel İ; Ayter S
    Childs Nerv Syst; 2018 May; 34(5):877-882. PubMed ID: 29455242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response of NF1-related plexiform neurofibroma to high-dose carboplatin.
    Hummel T; Anyane-Yeboa A; Mo J; Towbin A; Weiss B
    Pediatr Blood Cancer; 2011 Mar; 56(3):488-90. PubMed ID: 21225936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
    Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
    Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Exclusive nodular plexiform neurofibroma. An unusual case of neurofibromatosis type 1].
    Benchikhi H; Zeller J; Wolkenstein P; Wechsler J; Vidaud D; Revuz J
    Ann Dermatol Venereol; 1995; 122(9):601-3. PubMed ID: 8745684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
    Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
    Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
    Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
    Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.